tazarotene
Fuentes regulatorias consultadas
Indicaciones aprobadas
- Psoriasis en placas leve o moderada que afecta hasta el 10% de la superficie corporal.
Contraindicaciones
Absolutas
- Hipersensibilidad, embarazo, planificación de embarazo o lactancia.
- Psoriasis pustular o exfoliativa; no aplicar en pliegues, cara ni cuero cabelludo con pelo.
Advertencias clínicas
- Advertencia mayor · Evitar piel sana, eczematosa o inflamada, ojos y luz UV excesiva. Suspender ante irritación. Precaución con fármacos fotosensibilizantes y evitar productos tópicos irritantes o muy desecantes. — CIMA ZORAC 0,05% gel, registro 61862
Eventos adversos
Comunes (≥1%)
Prurito · Quemazón · Eritema · Irritación · Descamación o sequedad
Embarazo y lactancia
Contraindicado durante el embarazo y la lactancia. En mujeres con capacidad reproductiva, obtener una prueba de embarazo negativa dentro de las 2 semanas previas al inicio, comenzar durante un periodo menstrual normal y usar anticoncepción adecuada durante el tratamiento.
Bibliografía reciente (PubMed)
Acne vulgaris commonly affects adults, adolescents, and preadolescents aged 9 years or older. The objective of this study was to provide evidence-based recommendations for the management of acne. A work group conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations. This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements. Analysis is based on the best available evidence at the time of the systematic review. These guidelines provide evidence-based recommendations for the management of acne vulgaris.
Nowadays, numerous skincare routines are used to rejuvenate aging skin. Retinoids are one of the most popular ingredients used in antiaging treatments. Among the representatives of retinoids, tretinoin is considered the most effective agent with proven antiaging effects on the skin and can be found in formulations approved as medicines for topical treatment of acne, facial wrinkles, and hyperpigmentation. Other retinoids present in topical medicines are used for various indications, but only tazarotene is also approved as adjunctive agent for treatment of facial fine wrinkling and pigmentation. The most commonly used retinoids such as retinol, retinaldehyde, and retinyl palmitate are contained in cosmeceuticals regulated as cosmetics. Since clinical efficacy studies are not required for marketing cosmetic formulations, there are concerns about the efficacy of these retinoids. From a formulation perspective, retinoids pose a challenge to researchers as a result of their proven instability, low penetration, and potential for skin irritation. Therefore, novel delivery systems based on nanotechnology are being developed to overcome the limitations of conventional formulations and improve user compliance. In this review, the clinical evidence for retinoids in conventional and nanoformulations for topical antiaging treatments was evaluated. In addition, an overview of the comparison clinical trials between tretinoin and other retinoids is presented. In general, there is a lack of evidence from properly designed clinical trials to support the claimed efficacy of the most commonly used retinoids as antiaging agents in cosmeceuticals. Of the other retinoids contained in medicines, tazarotene and adapalene have clinically evaluated antiaging effects compared to tretinoin and may be considered as potential alternatives for antiaging treatments. The promising potential of retinoid nanoformulations requires a more comprehensive evaluation with additional studies to support the p
Chronic ultraviolet (UV) exposure is the primary cause of skin photoaging, leading to wrinkles, pigmentation changes, and loss of dermal elasticity. This systematic review and network meta-analysis evaluated the efficacy and safety of topical compounds for treating skin photoaging. A comprehensive search identified 23 RCTs with 3905 participants, comparing anti-aging agents. Bayesian network meta-analysis showed isotretinoin, retinol, and tretinoin significantly improved fine wrinkles, with isotretinoin ranked highest. Tazarotene was most effective for coarse wrinkles, while glycolic acid reduced roughness. Tretinoin and retinol were superior for hyperpigmentation. Safety analysis indicated tretinoin had the most favorable profile, whereas tazarotene and glycolic acid had higher adverse event risks. Isotretinoin and tretinoin emerged as the most balanced treatments across efficacy and safety. These findings provide evidence-based guidance for clinical decision-making in anti-photoaging therapy and underscore the potential for these agents to be integrated into routine dermatologic practice, particularly for patients seeking effective and well-tolerated topical interventions. However, limitations included limited racial diversity, potential commercial bias, and variability in dermatological assessments. These findings provide evidence-based guidance for clinical decision-making in anti-photoaging therapy.
Seborrheic keratoses (SKs) are benign epidermal neoplasms presenting as waxy, brown to black papules and plaques. Patients often seek removal for cosmetic reasons or irritation. The objective of this systematic review is to assess the efficacy and safety of topical treatments for SKs. Studies involving any topical medication indicated for SK removal were retrieved from Embase, Scopus, PubMed, and Cochrane. The final search was conducted on November 9, 2021, and 26 reports met inclusion criteria. A quality rating scheme was utilized to assess evidence quality. Heterogeneity of treatments and outcome measures precluded meta-analysis. Topical treatments that yielded a good-to-excellent response include hydrogen peroxide, Maxacalcitol 25 µg/g, BID Tazarotene 0.1% cream, 5% potassium dobesilate cream, 1% diclofenac sodium solution, urea-based solution, and 65% and 80% trichloroacetic acid. Local skin reactions were often mild and transient. Topical hydrogen peroxide showed the greatest evidence for clinical clearance of SKs, although there are no studies to our knowledge that directly compared hydrogen peroxide to current first-line treatments (e.g. cryotherapy or shave excision). The results of this review suggest viable and safe treatment of SK with topical therapies; however, there remains demand for topical treatments that reliably equate or exceed the efficacy of current first-line therapies.Key PointsQuestion: Are safe and efficacious topical treatments for seborrheic keratoses available?Findings: Topical treatments for seborrheic keratoses yield different responses and may be associated with local skin reactions. Topical hydrogen peroxide shows the greatest evidence for clinical clearance of seborrheic keratoses and may be a viable option for patients requesting noninvasive removal. No studies to our knowledge directly compare hydrogen peroxide to current first-line treatments.Meaning: There remains demand for topical treatments that reliably equate or exceed the